Stockreport

AbCellera (ABCL) Is Up 24.5% After Strong Q2 Revenue Beat and Advancing Clinical Pipeline [Yahoo! Finance]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF significant milestone payment from a Trianni license, alongside the initiation of a Phase 1 trial for its investigational antibody therapy ABCL575 and appointment of a n [Read more]